Adaptive Biotechnologies
Nasdaq ADPT · Seattle, WA
Works in Cardiovascular · GI & liver · Hematology · Immunology · Infectious disease · Oncology · Respiratory
Adaptive Biotechnologies is a clinical trial sponsor based in Seattle, WA, listed as Nasdaq ADPT. It has 1 active clinical trial with 300 planned participants, across 7 therapeutic areas. Since 2021 it has completed 4 trials and stopped 3 early.
Trial track record · since 2021
Financials · Nasdaq ADPT
Pipeline · 1 active trial
| Stage | Trial | Status |
|---|---|---|
Questions about Adaptive Biotechnologies
Adaptive Biotechnologies is lead sponsor of 1 active clinical trial on ClinicalTrials.gov, with 300 planned participants, in Cardiovascular, GI & liver, Hematology, Immunology and other areas. Since 2021 it has completed 4 trials and stopped 3 early.
Adaptive Biotechnologies is based in Seattle, WA and is listed as Nasdaq ADPT. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Adaptive Biotechnologies; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2024-08-22.
Approve Suite is not affiliated with Adaptive Biotechnologies.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.